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1. Introduction  
Many infections occur more frequently in the elderly and are often associated with 
morbidity and mortality. Pneumonia, particularly due to Streptococcus pnuemoniae, is the 
most frequent cause of death in geriatric patients. After suffering influenza, there is a 
problem in that the elderly tend to get pneumonia as an influenza-related disease. 
Therefore, annual immunization against influenza and pneumococcal vaccines at the age of 
65 years are recommended for all adults who are 65 years old and older (1). In this review, 
we address whether the protective efficacy of the influenza vaccine and 23-valent 
pneumococcal polysaccharide vaccine (PPV23) in the elderly with and without chronic 
obstructive pulmonary disease can be shown among recent epidemiological studies. 
2. Important 
Routine annual influenza vaccination is recommended for all persons aged 6 months and 
above (1,2). The elderly are considered a high risk group, because the risks for complications, 
hospitalizations, and deaths are higher among adults aged 65 years and older, in spite of 
rates of infection from seasonal influenza being highest among children. It should be 
considered that the elderly with poor physical and nutritional status tended to respond 
poorly to the influenza vaccination.  
In addition to annual influenza vaccination, all persons should be vaccinated with PPV23 at 
age 65 years to prevent invasive pulmonary diseases in all-cause pneumonia or mortality (3). 
Even though it is said the immune response of the elderly is likely to be declined, almost all 
persons older than 65 years indicate antibody elevations above clinical effective response 
after vaccination of influenza and/or PPV23. The introduction of the 7-valent pneumococcal 
conjugate vaccine (PCV7) in children may alter the vaccine-preventable disease burden in 
older adults and, correspondingly, the potential magnitude of the benefit of PPV23(4). 
3. Information 
3.1 Influenza 
The elderly have been considered the priority group for influenza vaccination, but their 
influenza vaccine-induced antibodies were believed to decline more rapidly than young 
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adults. Song et al. evaluated long-term immunogenicity of the influenza vaccine among the 
elderly (5). Serum hemagglutinin inhibition (HAI) titers were determined at pre- and post-
vaccination periods. Of the 1,018 subjects, 716 (70.3%) were followed up during a 12-month 
period. Seroprotection rates at 4 weeks post-vaccination ranged from 70.1% to 90.3% 
depending on the age group and influenza vaccine virus strain. At 6 months post-
vaccination, seroprotection rates for all three strains had declined significantly in adults 65 
years old or older (P<0.01) as compared to young adults.  
Hara et al. also assessed the immune response and serum nutritional status of 153 elderly 
residents of nursing homes (mean age 84.4 years) to the influenza vaccine (6). Post-
vaccination of HAI titers to A/H1N1 and B were low compared to young adults. However, 
seroconversion rates, which indicated greater than or equal to a fourfold rise for A/H1N1 
and A/H3N2, were unexpectedly high among the elderly. Among all subjects, lower age 
and higher serum concentrations of total protein, albumin, Vitamin E and folate were 
associated with an intact immune response, e.g., post-vaccination HAI titers showed greater 
than 40 for at least one vaccine strain. In an age-adjusted analysis limited to the elderly, only 
Vitamin E showed a significant association with the immune response. These results 
suggested that Vitamin E may play an important role in maintaining the immune response, 
especially among the elderly. 
The other publication by Sagawa et al. has considered physical and nutritional factors (7). 
Pre- and post-vaccination HAI titers were determined for 203 individuals aged 65 years or 
older residing in a nursing home. For the assessment of physical and nutritional status, 
information was retrieved from care records. The immune response to the vaccination was 
assessed as good in 122 subjects based on a fourfold rise or more in HAI titer after 
vaccination for at least one of three vaccine strains. In a univariate logistic regression 
analysis with poor versus good immune response, factors found to be significantly 
associated with a poor immune response were disability, a combination of body mass index 
(BMI) less than 18.5 and body weight loss in 6 months or 5% or more, mid-upper-arm 
circumference of less than 80%, arm muscle circumference of less than 80% and total protein 
of less than 6.5 g/dL (Table 1). Physical and nutritional indicators might be useful in 
identifying individuals who are unlikely to have a good immune response to the influenza 
vaccination. In a multivariate analysis, the association remained significant for a low level of 
daily activities and a combination of BMI less than 18.5 and body weight loss in 6 months of 
5% or more. Elderly individuals with poor physical and nutritional status tended to respond 
poorly to the influenza vaccination compared to elderly with good status. A low level of 
daily activities and a combination of being underweight and having had recent body weight 
loss are good indicators of a poor immune response.  
According to the review by Skowronski DM(8), seroprotection rates of 70%-100% were 
maintained not just at 4 months but also at 5 months and even at >6 months, for the 
A/H3N2 and A/H1N1 vaccine components. Seroprotection rates appeared less consistent 
for the B vaccine component, throughout the postimmunization period. Seroconversion 
appears to vary substantially and inversely with preimmunization titers but not with age. 
The historic concern that the influenza vaccine-induced antibody response in the elderly 
declines more rapidly and below seroprotective levels within 4 months of immunization 
should be reconsidered. 
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3.2 Pneumococcal pneumonia 
Bacteremic pneumonia is the most common cause of invasive pneumococcal disease (IPD), 
accounting for 90% of all cases (9). There are over 90 different serotypes of S. pneumoniae, 
some are highly invasive whereas others rarely cause disease. Although there is variation in 
the serotype distribution between age groups and across different geographical populations, 
mortality associated with pneumococcal pneumonia in adults has remained unchanged at 
25% of all pneumonia deaths over the past 40 years (10). 
 
Variable 
Crude 
n (%) OR 95% CI 
Male 44 21.7 0.95 0.48–1.87 
Age ≥89 years 93 45.8 1.19 0.68–2.10 
Disability 178 88.0 0.25 0.07–0.69 
BMI <18.5 92 45.3 0.70 0.40–1.23 
Bodyweight loss in 6 months ≥5% 35 17.2 0.81 0.45–1.46 
BMI <18.5 and bodyweight loss in 6 months ≥5% 23 11.3 0.46 0.24–0.88 
AC <80% 33 15.8 0.45 0.21–0.97 
TSF <80% 104 51.2 0.88 0.50–1.55 
AMC <80% 21 10.3 0.37 0.14–0.92 
Diabetes 33 16.3 0.57 0.27–1.20 
Pulmonary disease 15 7.4 1.33 0.45–4.40 
Total protein <6.5 g/dL 63 31.0 0.52 0.29–0.95 
Albumin <3.4 g/dL 52 25.6 0.74 0.36–1.53 
Zinc <54 µg/dL 54 26.6 1.03 0.58–1.83 
HDL cholesterol <43 mg/dL 52 25.6 1.08 0.57–2.09 
LDL cholesterol >156 mg/dL 52 25.6 0.65 0.37–1.15 
Mean ± standard deviation. AC, mid-upper-arm circumference; AMC, mid-upper-arm muscle 
circumference; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; 
TSF, triceps skinfold thickness. 
Table 1. Odds ratios (OR) with 95% confidence intervals (CI) of a good immune response for 
each subgroup (7) 
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Since 1997, the Advisory Committee on Immunization Practices (ACIP) has recommended 
to prevent IPD, i.e., bacteremia, meningitis or infection of other normally sterile sites 
through use of the PPV23 among all adults aged above 65 years and those adults aged 19-64 
years with underlying medical conditions that put them at greater risk for serious 
pneumococcal infection (11). The updated recommendations (３) in 2010 include the following 
changes from 1997 ACIP recommendations: 1) the indications for which PPV23 vaccination 
is recommended include smoking (12) and asthma (13,14), and 2) routine use of PPV23 is no 
longer recommended for Alaska natives or American Indians aged below 65 years unless 
they have medical or other indications for PPV23 (15).  
It has been reported that the antibody concentration level rose more than 1μg/ml (so-called 
protective level for vaccine-related pneumonia) referring to one muscle (or subcutaneous) 
injection of PPV23 among almost all of the elderly subjects (16). As the antibody levels among 
14 serotypes can be commercially measured as showing in Figure 1, some several serotypes 
showed a level of more than 1μg/ml even before vaccination in among the elderly.  
 
Type-specific IgG antibody levels to Streptococcus polysaccharide 
Note: All types illustrated significantly (p<0.05) except type 3 and 4. 
Fig. 1. The concentration of the type-specific IgG antibodies before and after PPV23 
vaccination among elderly (mean±SE) (   Before vaccination   After vaccination ) (16) 
The Cochrane Collaboration supports the use of PPV23 to prevents invasive pulmonary 
diseases in all-cause pneumonia or mortality (17) by prospective, randomized controlled trials 
(RCTs) or quasi-randomised trials that compared PPV23 with placebo, control vaccines, or 
no intervention. The studies included participants at elevated risk of pneumococcal disease 
due to older adults aged 50 to 85 years with previous hospital admission for community-
acquired pneumonia in Sweden (18) and community-based older adults in Finland (19).Ten 
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studies involving 35,483 participants were included for outcome as IPD all causes with 15 
events in the vaccinated group and 60 events in the control group, even though a subgroup 
analysis for the elderly was not performed. PPV23 reduced overall risk for IPD with was a 
pooled estimated odds ratio (OR) of 0.26 (95% confident interval (CI) 0.15 to 1.46; random-
effects model). PPV23 was shown to be effective against all-cause pneumonia with a pooled 
estimated OR of 0.71 (95% CI 0.52 to 0.97) by a random-effects model. There was no 
evidence of protective efficacy against all-cause mortality, with a pooled estimated OR of 
0.87 (95% CI 0.69 to 1.10; random-effects model). Enen though this meta-analysis has failed 
to demonstrate evidence for pneumococcal polysaccharide vaccination effectiveness against 
mortality (all cause or pneumococcal related), it demonstrates strong evidence of protection 
against IPD, with a correlate of efficacy from the RCTs of 74% (95% CI 56% to 85%) as 
shown in Fig 2.  
 
Fig. 2. Odds ratios (OR) with 95% confidence intervals (CI) of Comparison of RCTs of 
vaccination versus placebo for PPV23 vaccination (modified from article 17) 
Observational studies have suggested effectiveness estimates ranging from approximately 
50% to 80% for prevention of IPD among immunocompetent older adults and adults with 
various underlying illnesses, supporting the recommendations for using PPV23 to prevent 
IPD (20), although the effectiveness has not been demonstrated among immunocompromised 
persons or very old persons. A recent meta-analysis of 15 RCTs and seven non-randomized 
observational studies of PPV23 efficacy and effectiveness suggested an overall efficacy of 
74% against IPD (CI = 56%-85%), based on pooled results of 10 of the RCTs (21). Analysis of 
the results from the seven observational studies yielded a pooled vaccine effectiveness 
estimate of 52% (CI = 39%--63%). In contrast, a recent meta-analysis that included six RCTs 
estimated the combined PPV23 efficacy against pneumococcal bacteremia at only 10%, with 
a very wide CI (CI = -77%--54%) (13).  
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Regarding revaccination, ACIP recommendations for revaccination with PPV23 among the 
adult patient groups at greatest risk for IPD (i.e., persons with functional or anatomic 
asplenia and persons with immunocompromising conditions) remain unchanged. ACIP 
does not recommend routine revaccination for most persons for whom PPV23 is indicated. 
A second dose of PPV23 is recommended 5 years after the first dose for persons aged 19--64 
years with functional or anatomic asplenia and for persons with immunocompromising 
conditions. ACIP does not recommend multiple revaccinations because of uncertainty 
regarding clinical benefit and safety. 
It is said the changing epidemiology of IPD following the introduction of the 7-valent 
pneumococcal conjugate vaccine (PCV7) in children has altered the vaccine-preventable 
disease burden in older adults and, correspondingly, the potential magnitude of the benefit 
of PPV23 (22). Finally, newer vaccines, such as PCV7 (23,24) or those employing serotype-
independent antigens, offer the potential to provide clinical protection against 
pneumococcal infection in the growing population of older adults in the 21st century. In 
summary, the decrease in rates of pneumonia (25) and IPD among young children after the 
introduction of PCV7 indicates that eliciting protective immunity against invasive and non-
invasive pneumococcal infections by vaccination is a realistic goal. The unconjugated 
polysaccharide vaccine has reduced the risk of IPD among older adults, and protein-
conjugated vaccines have provided substantial direct benefits to children and indirect 
benefits to adults. Future opportunities to further reduce the risk of pneumococcal infections 
in adults will depend on advances in our understanding of the mechanisms of protective 
responses to S. pneumoniae in the systemic and, particularly, in the respiratory mucosal 
compartments.  
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